Life
Stealth biotech Stipple bets on secretive ADCs
Strategic angle: How thin science fuels peptide hype, blowback to proposed NIH cuts, and more biotech news from The Readout
editorial-staff
1 min read
Updated 5 days ago
Stipple is positioning itself in the competitive biotech landscape by focusing on antibody-drug conjugates (ADCs), a strategy that may influence market dynamics in therapeutic development.
The company's reliance on peptide technology raises questions about the robustness of the underlying science, particularly as it faces scrutiny from funding bodies like the NIH.
Proposed cuts to NIH funding could have cascading effects on research and development in the biotech sector, potentially impacting innovation and investment in companies like Stipple.